Home News Kiadis Pharma to present at…

Amsterdam, The Netherlands, September 15, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that Manfred Rüdiger, CEO, will present at the annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 7-9 2015 in La Jolla, California.

At the meeting, Manfred will provide an update on the Company, its pipeline, discuss the current challenges and shortcomings associated with unrelated donor transplantations and the potential of its lead product ATIR™101, which is currently being tested in an open-label Phase II trial, to address these unmet medical needs. This conference is the sector’s premiere forum bringing together senior executives and top decision makers in the industry within the scientific community with the shared goal of advancing and translating cutting-edge research into revolutionary treatments and cures.

Co-hosted by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the 2015 Stem Cell Meeting on the Mesa is a three-day conference featuring a two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium.

At the Partnering Forum, held October 7 and 8, industry executives will lead in-depth, interactive panels and workshops to discuss critical commercial issues facing the sector today.

The nationally recognized Scientific Symposium, held October 9 at the Salk Institute for Biological Studies, will showcase leading academic research in the field of regenerative medicine and advanced therapies.

Stem Cell Meeting on the Mesa is expected to attract nearly 800 attendees, including leading cell therapy, gene therapy and tissue engineering companies, large pharma and biotech, industry investors and major academic research institutions.

The following are specific details regarding Kiadis Pharma’s presentation at the conference:

Event: 2015 Stem Cell Meeting on the Mesa – Partnering Forum

Date: Wednesday, October 7

Time: 3:15pm

Location: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037

A live video webcast of all company presentations will be available at: http://stemcellmeetingonthemesa.com/webcast/ and will also be published on ARM’s website shortly after the event.

Please visit http://stemcellmeetingonthemesa.com/ for full information including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Laura Parsons at lparsons@alliancerm.org and interested media should contact Lyndsey Scull at lscull@alliancerm.org.

About ATIR™

During an allogeneic hematopoietic stem cell transplantation (HSCT) treatment, the bone marrow, harbouring the diseased cells, is completely destroyed and subsequently replaced by stem cells from a healthy donor. After an HSCT treatment it usually takes at least six to twelve months to recover to near-normal blood cell levels and immune cell functions in a patient that has received a transplant. During this period, the patient is highly susceptible and vulnerable to infections caused by bacteria, viruses and fungi. Immune cells in ATIR(Allodepleted T-cell ImmunotheRapeutics) will help fight these opportunistic infections and bridge the time until the immune system has fully re-grown from stem cells in the transplanted graft.

In ATIR, T-cells that cause Graft-versus-Host-Disease (GVHD) are eliminated from the donor lymphocytes, which minimises the risk of GVHD and any related morbidity and mortality. At the same time, ATIRcontains potential cancer killing T-cells from the donor that could eliminate residual cancer cells and avoid the return of the disease. ATIRallows the use of haploidentical grafts that are almost entirely depleted of T-cells, which eliminates the need for immunosuppressive drugs. ATIRsubsequently provides the patient with immune cells that do not cause GVHD. As a result, ATIRsolves the problem of not finding a matched donor in time and has the potential to make curative HSCT a viable option to many more patients.

The Company estimates that approximately 35% of patients who are eligible for, and who are in urgent need of, HSCT will not find a matching donor in time. A partially matched (haploidentical) family donor, however, will be available to over 95% of patients. The use of haploidentical donor grafts without ATIR™ is only feasible in conjunction with severe immunosuppression which renders the patient highly vulnerable to infections with severe clinical complications, resulting potentially in death.

About Kiadis Pharma

Kiadis Pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The Company believes that its innovative products have the potential to address the current risks and limitations connected with allogeneic hematopoietic stem cell transplantation (HSCT). Although currently not a viable option for many patients, HSCT is generally regarded as the most effective curative approach to blood cancers and certain inherited blood disorders. The Company expects that HSCT could become a first-choice treatment for blood cancers and inherited blood disorders once current risks and limitations are addressed, thereby meeting a significant unmet medical need with its products.

Currently, ATIR™101 is being tested in an open-label Phase II trial in patients with blood cancer who have not found a matching donor and where a partially matched (haploidentical) family member is used as donor for HSCT. Kiadis Pharma recently announced full enrolment of this trial.

Kiadis Pharma is based in Amsterdam, the Netherlands and its shares are listed on Euronext Amsterdam and Euronext Brussels. Further information can be found at: www.kiadis.com

For more information, please contact:
Manfred Rüdiger, CEO
Kiadis Pharma
Entrada 231-234
1114 AA Amsterdam-Duivendrecht
The Netherlands
Tel. +31 20 314 02 50
communication@kiadis.com

International Media and Investor Contact:
Mary-Jane Elliott, Lindsey Neville, Hendrik Thys
Consilium Strategic Communications
Tel: +44 (0) 203 709 5708
kiadis@consilium-comms.com

Forward Looking Statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma’s or, as appropriate, Kiadis Pharma’s directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.